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Abstract
Objective—An improved understanding of carbapenem-resistant Klebsiella pneumoniae (CRKP) 
in long-term acute care hospitals (LTACHs) is needed. The objective of this study was to assess 
risk factors for colonization or infection with CRKP in LTACH residents.
Methods—A case-control study was performed at a university-affiliated LTACH from 2008 to 
2013. Cases were defined as all patients with clinical cultures positive for CRKP and controls 
were those with clinical cultures positive for carbapenem-susceptible K. pneumoniae (CSKP). A 
multivariable model was developed to identify risk factors for CRKP infection or colonization.
Results—222 patients were identified with K. pneumoniae clinical cultures during the study 
period; 99 (45%) were case patients and 123 (55%) were control patients. On multivariable 
analysis, factors associated with a significant risk for CRKP colonization or infection were solid 
organ or stem cell transplantation (OR, 5.05; 95% CI, 1.23 – 20.8, P=0.03), mechanical ventilation 
(OR, 2.56; 95% CI, 1.24 – 5.28, P=0.01), fecal incontinence (OR, 5.78; 95% CI, 1.52 – 22.0, 
P=0.01), and exposure in the prior 30 days to meropenem (OR, 3.55; 95% CI, 1.04 – 12.1, 
P=0.04), vancomycin (OR, 2.94; 95% CI, 1.18 – 7.32, P=0.02), and metronidazole (OR, 4.22; 95% 
CI, 1.28 – 14.0, P=0.02).
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Conclusions—Rates of colonization and infection with CRKP were high in the LTACH setting, 
with nearly half of K. pneumoniae cultures demonstrating carbapenem resistance. Further studies 
are needed on interventions to limit the emergence of CRKP in LTACHs, including targeted 
surveillance screening of high-risk patients and effective antibiotic stewardship measures.
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INTRODUCTION
Infections due to carbapenem-resistant Enterobacteriaceae (CRE) are associated with high 
mortality rates and limited antibiotic treatment options1–6. Since the initial identification of a 
Klebsiella pneumoniae carbapenemase (KPC)-producing K. pneumoniae isolate in 1996, 
CRE have rapidly disseminated worldwide5,7. Although multiple genera of 
Enterobacteriaceae have been found to carry carbapenemase enzymes, carbapenem-resistant 
Klebsiella pneumoniae (CRKP) remains the most epidemiologically important in the United 
States. Recent studies have emphasized the increasing importance of long-term acute care 
hospitals (LTACHs) as reservoirs and regional amplifiers of CRKP, with up to 9-fold higher 
prevalence rates of colonization compared to those in acute care hospitals8–11.
Residents of LTACHs are at increased risk for colonization and infection with CRKP for a 
number of reasons. LTACHs care for a chronically, critically ill patient population that is 
characterized by significant debility, prolonged durations of stay, and high rates of invasive 
device utilization and antibiotic exposure12. Understanding the epidemiology of CRKP in 
LTACHs is critical for the development of infection prevention and antibiotic stewardship 
measures to reduce the emergence of these organisms in the long-term care setting. 
However, prior studies assessing risk factors for CRE acquisition in LTACHs have been 
performed during ongoing outbreaks13,14. High levels of colonization pressure during acute 
outbreaks with multidrug-resistant organisms increases the risk for horizontal transmission, 
and may not reflect transmission dynamics in other settings15.
Therefore, given the limited data on the epidemiology of CRKP in LTACHs in the non-
outbreak setting, we performed a case-control study to identify risk factors for infection or 
colonization with CRKP in LTACH residents.
METHODS
Study design
A retrospective case-control study was performed at a 38-bed, freestanding LTACH within 
the University of Pennsylvania Health System to identify risk factors for CRKP infection or 
colonization. Per institutional policy, all patients at the facility have surveillance blood, 
urine, and sputum or tracheal aspirate cultures performed routinely on admission. Clinical 
cultures obtained following admission are ordered at the discretion of treating physicians. 
Contact precautions are implemented for patients with positive CRKP cultures for the 
duration of their stay. The facility did not institute universal preemptive contact precautions 
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prior to surveillance culture results during the study period. All patients in the facility are 
housed in single rooms. The study was reviewed and approved by the Institutional Review 
Boards of the University of Pennsylvania and Good Shepherd Penn Partners.
All microbiologic isolates were processed at the Hospital of the University of Pennsylvania 
(HUP) Clinical Microbiology Laboratory. Standard identification and susceptibility testing 
of K. pneumoniae isolates was performed using the semiautomated Vitek 2 identification 
and susceptibility system (bioMérieux, Durham, NC) and interpreted according to Clinical 
and Laboratory Standards Institute (CLSI) criteria16. Confirmatory KPC polymerase chain 
reaction (PCR) testing was performed for isolates with a meropenem MIC of 2 μg/mL and 
ertapenem MIC < 1 μg/mL, or a meropenem MIC ≤ 2 μg/mL and ertapenem MIC ≥ 1 
μg/mL.
CRKP isolates were tested for susceptibility to tigecycline and colistin or polymyxin B using 
Etest (bioMérieux, Durham, NC), with isolates with an MIC of ≤ 2 μg/mL determined to be 
susceptible. Fosfomycin susceptibility was performed using the disk diffusion method as per 
CLSI guidelines.
Study population
Case patients were defined as all patients with a clinical culture (surveillance culture or 
clinical culture during LTACH stay) positive for CRKP from July 1 2008 to July 1 2013. 
Control patients were defined as all patients with a clinical culture positive for carbapenem-
susceptible K. pneumoniae (CSKP) over the same time period. Patients with positive 
cultures for both CRKP and CSKP during the study period were included as cases. Only the 
first positive K. pneumoniae culture was included for each unique patient.
Data collection
Data were abstracted from Penn Data Store, a comprehensive electronic database that 
includes demographic, laboratory, billing, and pharmacy information for all patients treated 
within the University of Pennsylvania Health System. The following variables were 
collected: demographics, comorbidities, length of stay (LOS) prior to K. pneumoniae culture 
positivity, location from which the patient was transferred (e.g., acute care hospital, 
rehabilitation facility), and study year. Comorbid conditions included diabetes mellitus, 
chronic kidney disease (CKD), chronic pulmonary disease, and malignancy, among others.
Use of antibiotics and immunosuppressive medications (e.g., tacrolimus, cyclosporine) 
within 30 days of the K. pneumoniae culture was also assessed. For purposes of analyses, 
antibiotics were classified as follows: aminoglycosides; fluoroquinolones; third-generation 
cephalosporins (i.e. ceftriaxone, ceftazidime); first-generation cephalosporins (i.e. 
cefadroxil, cefazolin, cephalexin); cefepime; ampicillin/sulbactam; piperacillin-tazobactam; 
meropenem; metronidazole; vancomycin; linezolid; clindamycin; trimethoprim-
sulfamethoxazole; tigecycline; and colistin. Finally, data on the use of mechanical 
ventilation and presence of a central venous or urinary catheter were collected via medical 
record review.
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Cases and controls were characterized by potential risk factors, including demographics, 
comorbidities, mechanical ventilation, indwelling device use, and antibiotic exposure. 
Descriptive statistics were conducted to characterize the entire study population. Bivariable 
analysis of all potential risk factors for CRKP infection or colonization was performed using 
Fisher's exact test for categorical variables and the Wilcoxon rank sum test for continuous 
variables. Odds ratios (OR) and 95% confidence intervals (CIs) were calculated to evaluate 
the strength of each association. Multivariable analyses were then performed using multiple 
logistic regression. All variables from bivariable analyses with P values <0.05 were 
evaluated and considered for inclusion in the final multivariable model. Backward stepwise 
selection was performed for selection of variables in the final explanatory model, with 
results confirmed using likelihood ratio testing17. For all calculations, a two-tailed P value of 
<0.05 was considered significant.
All analyses were performed using STATA v.13.0 (StataCorp, College Station, Texas).
RESULTS
Study population
A total of 222 unique patients had clinical cultures positive for K. pneumoniae during the 
study period. The mean age of patients was 69.8 years and 52% were female. The median 
length of stay prior to K. pneumoniae culture positivity was 6 days (interquartile range 
[IQR] 1– 19) for cases and 4 days (IQR 1 – 15) for controls, respectively (Table 1). Rates of 
central venous catheter and urinary catheter utilization were nearly 50% in both groups, with 
no statistical difference between cases and controls.
Ninety-nine (45%) of 222 K. pneumoniae isolates were identified as CRKP. Forty-three of 
these were isolated within 72 hours of admission, with 29 (67%) transferred from regional 
academic medical centers and 14 (33%) transferred from community medical centers.
The incidence rate of CRKP acquired after 72 hours of LTACH admission was 1.03 cases 
per 1,000 patient-days. No temporal trends were noted in CRKP incidence over the duration 
of the study period (data not shown).
Risk factors for colonization or infection with CRKP
On bivariable analysis (Table 1), there were no significant differences in age (P = 0.53), 
gender (P = 0.12), or length of LTACH stay prior to K. pneumoniae culture positivity (P = 
0.35) between cases and controls.
Colonization or infection with CRKP was significantly associated with non-white race and 
with the following comorbidities: solid organ or hematopoietic stem cell transplant, 
mechanical ventilation, cognitive impairment, tracheostomy, and fecal incontinence. There 
was also an association between CRKP and use of corticosteroids, immunosuppressants, 
vancomycin, cefepime, meropenem, and metronidazole within the prior 30 days.
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On subsequent multivariable analyses (Table 2), the following variables were significant risk 
factors for infection or colonization with CRKP: solid organ or hematopoietic stem cell 
transplant (OR, 5.05; 95% CI, 1.23 – 20.8, P=0.03), mechanical ventilation (OR, 2.56; 95% 
CI, 1.24 – 5.28, P=0.01), and fecal incontinence (OR, 5.78; 95% CI, 1.52 – 22.0, P=0.01). 
Administration of the following antibiotics within the prior 30 days was also significantly 
associated with CRKP isolation: meropenem (OR, 3.55; 95% CI, 1.04 – 12.1, P=0.04), 
vancomycin (OR, 2.94; 95% CI, 1.18 – 7.32, P=0.02), and metronidazole (OR, 4.22; 95% 
CI, 1.28 – 14.0, P=0.02).
Antibiotic susceptibility profiles of CRKP isolates
Sixteen (17%) of 93 CRKP isolates had a meropenem MIC of 1 μg/mL and 17 (18%) 
isolates had a meropenem MIC of 2 μg/mL. All of these isolates tested positive for KPC by 
PCR. The remaining 60 CRKP isolates had an MIC >2 μg/mL. Table 3 demonstrates 
susceptibility profiles of CRKP isolates. Overall, there was a relatively low rate of resistance 
to amikacin (31%). Fifty-two of the CRKP isolates underwent tigecycline susceptibility 
testing, with the majority (83%) identified as susceptible. Forty-nine (94%) of 52 tested 
CRKP isolates were susceptible to colistin or polymyxin B.
DISCUSSION
In this case-control study, nearly half (45%) of K. pneumoniae isolates identified by clinical 
cultures in a university-affiliated LTACH over a five-year period were resistant to 
carbapenems. Risk factors for CRKP infection or colonization included solid organ or 
hematopoietic stem cell transplantation, mechanical ventilation, fecal incontinence, and use 
of vancomycin, meropenem, or metronidazole in the prior 30 days
The results of our study are notable for a high rate of colonization or infection with CRKP in 
the study population, with nearly half of K. pneumoniae isolates demonstrating resistance to 
carbapenems. The high incidence rate of CRKP found in our study in a non-outbreak setting 
is of major concern, and is nearly fivefold the prevalence reported from acute care 
hospitals18. Notably, 43% of CRKP isolates were detected within 72 hours of arrival to the 
LTACH, suggesting presence on admission versus acquisition in the LTACH. CRKP isolates 
identified later during hospitalization may have been acquired through horizontal 
transmission or through detection of CRKP colonization that preceded admission. While 
detection of CRKP was likely facilitated through the use of admission clinical culture 
screening, this finding underscores the importance of LTACHs in the regional epidemiology 
of CRKP emergence and dissemination. Knowledge of local prevalence rates of CRKP are 
essential to coordinating a regional approach to CRE control, including enhanced inter-
facility communication between LTACHs, acute care hospitals, and long-term care facilities, 
and engagement of local health departments in regional surveillance efforts19. Furthermore, 
such high carbapenem resistance rates have important implications for infection prevention 
and antimicrobial stewardship measures specifically in the LTACH setting, including 
selection of an empiric antibiotic regimen for infections due to K. pneumoniae.
We found that solid organ and hematopoietic stem cell transplant recipients were at 
increased risk for CRKP infection or colonization. Prior transplantation was previously 
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identified as a risk factor for CRKP in an acute-care hospital in New York20, but to our 
knowledge, our study is the first to confirm this association in the LTACH setting. Transplant 
patients are at significant risk for colonization and/or infection with CRKP due to 
immunosuppression and high rates of antibiotic use. Given frequent hospitalizations and 
inter-facility transfers, these patients may also play an important role in the regional 
dissemination of CRKP21. Targeted active surveillance and/or pre-emptive isolation 
precautions on admission to an LTACH in this patient population may be of particular 
benefit and should be explored in future studies.
We also found that requirement for mechanical ventilation was a significant risk factor for 
colonization or infection with CRKP. Mechanical ventilation is a well-described risk factor 
for CRKP acquisition in acute-care hospitals20,22. The vast majority of ventilated LTACH 
patients have antecedent intensive care unit (ICU) stays and higher rates of invasive device 
utilization, increasing their risk for colonization or infection with multidrug-resistant 
organisms. As ventilation-dependent respiratory failure is the leading admission diagnosis to 
LTACHs12, this represents a substantial at-risk population contributing to increased CRKP 
colonization pressure, and could be targeted with enhanced surveillance measures as part of 
a coordinated regional CRKP control plan.
Fecal incontinence was also associated with an increased risk of CRKP in LTACH residents. 
While a study performed in a single LTACH23 demonstrated that only 0.5% of 
environmental isolates were positive for CRKP, recent studies have implicated 
environmental sources as contributing factors to ongoing CRKP outbreaks4,24. While the 
role of the environment in the transmission of CRE is still unclear, fecal incontinence likely 
leads to increased environmental contamination and subsequent risk for CRKP transmission. 
Fecal incontinence is also likely a surrogate for higher dependence on healthcare staff for 
hygiene and care, with increased opportunities for healthcare worker and patient contact and 
horizontal transmission of multidrug-resistant organisms. The potential benefit of enhanced 
precautions (i.e., gown and glove use in LTACH residents with fecal incontinence) should be 
explored in future studies.
Our analysis of recent antibiotic use found that meropenem, vancomycin, and metronidazole 
were risk factors for CRKP infection or colonization. Carbapenem use and its association 
with CRKP acquisition has been well-described in the acute-care hospital setting20,25. The 
use of broad-spectrum antibiotics, such as those identified in our study, likely exert broad 
colonization pressure and may select for colonization and/or infection with more resistant 
strains. Antibiotic utilization is widespread in LTACHs, with rates of vancomycin and 
carbapenem consumption between the 50th and 75th percentiles of medical ICUs15. Effective 
and feasible antibiotic stewardship measures are urgently needed in this setting.
There are several limitations of this study. Given that rectal culture for detection of 
asymptomatic gastrointestinal colonization was not routinely performed, our results likely 
underestimated the true burden of CRKP colonization. While our study did not include 
species of Enterobacteriaceae other than K. pneumoniae, thereby potentially underestimating 
the degree of overall CRE infection or colonization, data from a prior CRE screening 
program found that 90% of CRE isolates at our institution are CRKP. Finally, the present 
Mills et al. Page 6













study was conducted in a university-affiliated LTACH, and these results may not be 
generalizable to other LTACHs with differing characteristics.
In conclusion, solid organ or hematopoietic stem cell transplantation, mechanical 
ventilation, and fecal incontinence were found to be independent risk factors for CRKP 
infection or colonization in LTACH residents. Patients with these risk factors represent a 
population who may benefit from enhanced CRKP surveillance measures, including on a 
regional basis. Recent exposure to meropenem, vancomycin, and metronidazole were also 
associated with increased risk of CRKP colonization or infection. Future studies are needed 
on optimal antimicrobial stewardship interventions specifically in the LTACH setting with 
the goal of reducing the emergence of CRKP.
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Table 1
Bivariable analysis of risk factors for infection or colonization with carbapenem-resistant K. pneumoniae in 




a OR (95% CI) P value
Age, median years (IQR) 72 (63–79) 72 (62–78) ---- 0.53
Female sex 46 (46) 70 (57) 0.66 (0.37–1.16) 0.12
Non-white race 67 (68) 65 (53) 1.87 (1.00–3.37) 0.03
Comorbidities
CHF 11 (11) 15 (12) 0.90 (0.35–2.22) 0.80
CKD 28 (28) 23 (19) 1.71 (0.87–3.39) 0.09
Cirrhosis 4 (4) 2 (2) 2.55 (0.36–28.6) 0.27
Diabetes 9 (9) 12 (10) 0.93 (0.33–2.52) 0.87
Obesity
b 2 (2) 7 (6) 0.34 (0.03–1.86) 0.17
Chronic lung disease 10 (10) 11 (9) 1.14 (0.41–3.12) 0.78
Malignancy 10 (10) 5 (4) 2.65 (0.79–10.2) 0.08
HIV infection 2 (2) 1 (1) 2.51 (0.13–150) 0.44
Cognitive impairment 18 (18) 7 (6) 3.68 (1.38–10.9) 0.003
Solid organ or hematopoietic stem cell transplant 12 (12) 3 (2) 5.52 (1.42–31.2) 0.004
Clostridium difficile colitis 9 (9) 6 (5) 1.95 (0.59–6.89) 0.21
Sacral decubitus ulcer 8 (8) 4 (3) 2.62 (0.67–12.2) 0.11
Fecal incontinence 13 (13) 3 (2) 6.05 (1.58–33.8) 0.002
Total parental nutrition 9 (9) 17 (14) 0.62 (0.23–1.57) 0.28
Mechanical ventilation 81 (82) 80 (67) 2.19 (1.11–4.42) 0.02
Tracheostomy 87 (90) 91 (77) 2.58 (1.12–6.32) 0.02
Gastrostomy 80 (82) 83 (70) 1.92 (0.97–3.91) 0.05
Central venous catheter 50 (53) 66 (56) 0.88 (0.49–1.56) 0.63
Urinary catheter 50 (51) 49 (41) 1.50 (0.84–2.64) 0.15
Medications
c
Corticosteroids 36 (36) 28 (23) 1.94 (1.03–3.65) 0.03
Immunosuppressants 17 (17) 6 (5) 4.04 (1.44–13.0) 0.003
Vancomycin 22 (22) 9 (7) 3.62 (1.50–9.38) 0.001
Cefepime 13 (13) 5 (4) 3.57 (1.13–13.2) 0.01
Meropenem 13 (13) 4 (3) 4.50 (1.32–19.5) 0.006
Metronidazole 15 (15) 6 (5) 3.48 (1.21–11.4) 0.009
Abbreviations: OR, odds ratio; CI, confidence interval; IQR, interquartile range; LOS, length of stay; CHF, congestive heart failure; CKD, chronic 
kidney disease.
a




Received within 30 days of the positive culture. Only variables with P<0.05 are shown.
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Table 2
Multivariable model of risk factors for infection or colonization with carbapenem-resistant K. pneumoniae in 
long-term acute care hospital residents.
Variable OR (95% CI) P value
Solid organ or hematopoeitic stem cell transplant 5.05 (1.23–20.8) 0.03
Mechanical ventilation 2.56 (1.24–5.28) 0.01
Fecal incontinence 5.78 (1.52–22.0) 0.01
Meropenem
a 3.55 (1.04–12.1) 0.04
Vancomycin
a 2.94 (1.18–7.32) 0.02
Metronidazole
a 4.22 (1.28–14.0) 0.02
Abbreviations: OR, odds ratio; CI, confidence interval.
a
Receipt within prior 30 days.
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Table 3
Antibiotic susceptibility profiles of carbapenem-resistant K. pneumoniae isolates.
Antibiotic Susceptible n (%) Intermediate n (%) Resistant n (%)
Amikacin 66 (69) ------- 30 (31)
Tigecycline
a 43 (83) 8 (15) 1 (2)
Colistin and/or Polymyxin B
a 49 (94) ------- 3 (6)
Fosfomycin
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